6.
Hernandez-Salazar A, Ponce-de-Leon Rosales S, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R
. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res. 2006; 37(7):899-902.
DOI: 10.1016/j.arcmed.2006.03.010.
View
7.
Ai Qun Oh D, Yeo Y, Choo K, Pang S, Oh C, Lee H
. Acute generalized exanthematous pustulosis: Epidemiology, clinical course, and treatment outcomes of patients treated in an Asian academic medical center. JAAD Int. 2021; 3:1-6.
PMC: 8362292.
DOI: 10.1016/j.jdin.2020.12.004.
View
8.
Wasuwanich P, So J, Chakrala T, Chen J, Motaparthi K
. Epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States and factors predictive of outcome. JAAD Int. 2023; 13:17-25.
PMC: 10413346.
DOI: 10.1016/j.jdin.2023.06.014.
View
9.
Bigby M
. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001; 137(6):765-70.
View
10.
Hunziker T, Kunzi U, Braunschweig S, Zehnder D, Hoigne R
. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997; 52(4):388-93.
DOI: 10.1111/j.1398-9995.1997.tb01017.x.
View
11.
Lee H, Tay L, Thirumoorthy T, Pang S
. Cutaneous adverse drug reactions in hospitalised patients. Singapore Med J. 2010; 51(10):767-74.
View
12.
Gilkey T, Trinidad J, Kovalchin C, Minta A, Rosenbach M, Kaffenberger B
. Defining Drugs that are High-Risk Associations for Drug Reactions Within the Hospital Setting. J Clin Aesthet Dermatol. 2022; 15(6):59-64.
PMC: 9239122.
View
13.
Hung S, Chung W, Liou L, Chu C, Lin M, Huang H
. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005; 102(11):4134-9.
PMC: 554812.
DOI: 10.1073/pnas.0409500102.
View
14.
Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W
. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2013; 149(9):1025-32.
DOI: 10.1001/jamadermatol.2013.4114.
View
15.
Li X, Yu K, Mei S, Huo J, Wang J, Zhu Y
. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res (Stuttg). 2014; 65(2):107-11.
DOI: 10.1055/s-0034-1375684.
View
16.
Chen W, Wang C, Lu C, Chen C, Lee H, Hung S
. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. J Invest Dermatol. 2018; 138(7):1546-1554.
DOI: 10.1016/j.jid.2018.02.004.
View
17.
van der Linden P, van der Lei J, Vlug A, Stricker B
. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol. 1998; 51(8):703-8.
DOI: 10.1016/s0895-4356(98)00041-9.
View
18.
Mokhtari F, Nikyar Z, Naeini B, Asemi Esfahani A, Rahmani S
. Adverse cutaneous drug reactions: Eight year assessment in hospitalized patients. J Res Med Sci. 2014; 19(8):720-5.
PMC: 4235091.
View
19.
Krispinsky A, Shedlofsky L, Kaffenberger B
. The frequency of low-risk morbilliform drug eruptions observed in patients treated with different classes of antibiotics. Int J Dermatol. 2019; 59(6):647-655.
DOI: 10.1111/ijd.14703.
View
20.
Stewart A, Lehloenya R, Boulle A, de Waal R, Maartens G, Cohen K
. Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. Pharmacoepidemiol Drug Saf. 2016; 25(11):1313-1319.
DOI: 10.1002/pds.4067.
View